EYN PG21

EYN PG21 is an investigational microdose ophthalmic formulation of **latanoprost 0.005%** delivered via Eyenovia's patented piezo-print Optejet technology, designed to precisely administer 6-8 µL doses matching the eye's tear film capacity. Developed by **Eyenovia** for reducing intraocular pressure (IOP), it demonstrated up to **29% diurnal IOP reduction** from baseline in a Phase 2 trial (EYN PG21) involving 30 healthy participants, comparable to standard latanoprost drops (up to 26%), with 95% investigator success and 88% patient self-administration success after brief training—far superior to traditional droppers (39-47%). This addresses glaucoma and ocular hypertension by minimizing over-dosing, preservative exposure, and variability while improving tolerability and compliance.[1][5][9]

Brand names

MicroProst

Other names

MicroProst